Search bioRxiv⌕ Search

Biology subjects

Gonzalez-Aponte, M. F.

Publications and source records attributed to Gonzalez-Aponte, M. F..

3 recordsLinked to original sources

Circadian Clock Gene Modulation and Selective Reprogramming in Response to Virus Infection

The circadian clock regulates fundamental cellular processes that include the host response to infection. However, the intersection of the circadian clock and the mechanisms that drive antiviral immunity remains poorly understood. Copy-back viral genomes (cbVGs) generated during virus replication strongly stimulate immunity during infection with negative-sense RNA viruses. Here, we demonstrate at the single cell level that A549 lung epithelial cells, commonly used to model lung infections, sustain circadian rhythms and upon infection with Sendai virus (SeV) progressively remodel the circadian clock through an innate immune response driven primarily by cbVGs. Furthermore, we show that cbVG-driven changes in circadian gene expression are mediated through two distinct innate immune sensing pathways: the RIG-I adaptor MAVS is required for preferential induction of the BMAL1 paralog ARNTL2, whereas the double-stranded RNA sensor PKR is required for the cbVG-specific induction of the negative-feedback regulators NR1D1, NR1D2, and PER1. A similar cbVG-specific signature was observed during respiratory syncytial virus infection, suggesting that cbVG-driven circadian gene regulation is not unique to SeV. In addition, we established through gain- and loss-of-function experiments that ARNTL2 is functionally required for amplifying the transcriptional response to infection, with selective effects on the expression of specific antiviral genes, including CCL5. Together, these findings establish innate immune signaling triggered by cbVGs as selective driver of circadian clock gene expression during viral infection through distinct sensing pathways and identify ARNTL2 as a previously unrecognized regulator of virus-induced host transcriptional responses.

microbiology↗

Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host

Glioblastoma (GBM) is the most common primary brain tumor in adults with a poor prognosis despite aggressive therapy. A recent, retrospective clinical study found that administering Temozolomide in the morning increased patient overall survival by 6 months compared to evening. Here, we tested the hypothesis that daily host signaling regulates tumor growth and synchronizes circadian rhythms in GBM. We found daily Dexamethasone promoted or suppressed GBM growth depending on time of day of administration and on the clock gene, Bmal1. Blocking circadian signals, like VIP or glucocorticoids, dramatically slowed GBM growth and disease progression. Finally, mouse and human GBM models have intrinsic circadian rhythms in clock gene expression in vitro and in vivo that entrain to the host through glucocorticoid signaling, regardless of tumor type or host immune status. We conclude that GBM entrains to the circadian circuit of the brain, which modulates its growth through clock-controlled cues, like glucocorticoids.

neuroscience↗

Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma

BackgroundGlioblastoma (GBM) is the most common primary brain tumor in adults. Despite extensive research and clinical trials, median survival post-treatment remains at 15 months. Thus, all opportunities to optimize current treatments and improve patient outcomes should be considered. A recent retrospective clinical study found that taking TMZ in the morning compared to the evening was associated with a 6-month increase in median survival in patients with MGMT-methylated GBM. Here, we hypothesized that TMZ efficacy depends on time-of-day and O6-Methylguanine-DNA Methyltransferase (MGMT) activity in murine and human models of GBM. Methods and ResultsIn vitro recordings using real-time bioluminescence reporters revealed that GBM cells have intrinsic circadian rhythms in the expression of the core circadian clock genes Bmal1 and Per2, as well as in the DNA repair enzyme, MGMT. Independent measures of MGMT transcript levels and promoter methylation also showed daily rhythms intrinsic to GBM cells. These cells were more susceptible to TMZ when delivered at the daily peak of Bmal1 transcription. We found that in vivo morning administration of TMZ also decreased tumor size and increased body weight compared to evening drug delivery in mice bearing GBM xenografts. Finally, inhibition of MGMT activity with O6-Benzylguanine abrogated the daily rhythm in sensitivity to TMZ in vitro by increasing sensitivity at both the peak and trough of Bmal1 expression. ConclusionWe conclude that chemotherapy with TMZ can be dramatically enhanced by delivering at the daily maximum of tumor Bmal1 expression and minimum of MGMT activity. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=164 SRC="FIGDIR/small/557630v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@2e9058org.highwire.dtl.DTLVardef@1069917org.highwire.dtl.DTLVardef@2cf000org.highwire.dtl.DTLVardef@40abc9_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗